180 related articles for article (PubMed ID: 36074798)
41. Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease.
Dong Y; Zhang L; Nong L; Wang L; Liang Z; Zhou D; Fajgenbaum DC; Ren H; Li J
Ann Hematol; 2018 Sep; 97(9):1641-1647. PubMed ID: 29732477
[TBL] [Abstract][Full Text] [Related]
42. Castleman disease and TAFRO syndrome: To improve the diagnostic consciousness is the key.
Zhou QY
World J Clin Cases; 2022 Feb; 10(5):1536-1547. PubMed ID: 35211591
[TBL] [Abstract][Full Text] [Related]
43. Retrospective cohort evaluation of non-HIV Castleman disease from a single academic center in Beijing, China.
Guo M; Nong L; Wang M; Zhang Y; Wang L; Sun Y; Wang Q; Liu H; Ou J; Cen X; Ren H; Dong Y
Ann Hematol; 2024 Jan; 103(1):153-162. PubMed ID: 37749319
[TBL] [Abstract][Full Text] [Related]
44. ADA2 Deficiency Mimicking Idiopathic Multicentric Castleman Disease.
Van Nieuwenhove E; Humblet-Baron S; Van Eyck L; De Somer L; Dooley J; Tousseyn T; Hershfield M; Liston A; Wouters C
Pediatrics; 2018 Sep; 142(3):. PubMed ID: 30139808
[TBL] [Abstract][Full Text] [Related]
45. [Not Available].
Galicier L; Schleinitz N
Rev Med Interne; 2022 Dec; 43(10S1):10S26-10S33. PubMed ID: 36657940
[TBL] [Abstract][Full Text] [Related]
46. Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6-directed therapy.
Mukherjee S; Martin R; Sande B; Paige JS; Fajgenbaum DC
Blood Adv; 2022 Jan; 6(2):359-367. PubMed ID: 34535010
[TBL] [Abstract][Full Text] [Related]
47. Castleman Disease Pathogenesis.
Fajgenbaum DC; Shilling D
Hematol Oncol Clin North Am; 2018 Feb; 32(1):11-21. PubMed ID: 29157613
[TBL] [Abstract][Full Text] [Related]
48. HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy.
Fajgenbaum DC; van Rhee F; Nabel CS
Blood; 2014 May; 123(19):2924-33. PubMed ID: 24622327
[TBL] [Abstract][Full Text] [Related]
49. Plasma HHV-8 viral load in HHV-8-related lymphoproliferative disorders associated with HIV infection.
Simonelli C; Tedeschi R; Gloghini A; Talamini R; Bortolin MT; Berretta M; Spina M; Morassut S; Vaccher E; De Paoli P; Carbone A; Tirelli U
J Med Virol; 2009 May; 81(5):888-96. PubMed ID: 19319955
[TBL] [Abstract][Full Text] [Related]
50. Are Patients with HHV-8 Associated Castleman Disease Successfully Treated with Rituximab at Risk of Subsequently Developing HHV-8 Negative (Idiopathic) Castleman Disease?
Ha G; Kwong K; Tanaka B; Nishimura Y; Chong C
Eur J Case Rep Intern Med; 2023; 10(7):003904. PubMed ID: 37455698
[TBL] [Abstract][Full Text] [Related]
51. Unicentric Castlemans disease. Symptoms, diagnostics and therapy.
Adam Z; Řehák Z; Adamová Z; Koukalová R; Pour L; Krejčí M; Boichuk I; Krejčí M; Štork M; Ševčíková S; Král Z
Vnitr Lek; 2021; 67(8):465-473. PubMed ID: 35459366
[TBL] [Abstract][Full Text] [Related]
52. HHV-8-Associated Multicentric Castleman Disease, a Diagnostic Challenge in a Patient With Acquired Immunodeficiency Syndrome and Fever.
Dunn R; Jariwal R; Venter F; Mishra S; Bhandohal J; Cobos E; Heidari A
J Investig Med High Impact Case Rep; 2022; 10():23247096221097526. PubMed ID: 35549932
[TBL] [Abstract][Full Text] [Related]
53. Diagnosis and management of Castleman disease.
Soumerai JD; Sohani AR; Abramson JS
Cancer Control; 2014 Oct; 21(4):266-78. PubMed ID: 25310208
[TBL] [Abstract][Full Text] [Related]
54. EBV+ HHV-8+ Multicentric Castleman Disease With Plasmablastic Aggregates in an HIV+ Man: An Evolving Clinicopathologic Entity.
Shivane A; Pearce A; Khatib N; Smith MEF
Int J Surg Pathol; 2018 Jun; 26(4):338-341. PubMed ID: 29198143
[TBL] [Abstract][Full Text] [Related]
55. Multicentric Castleman disease and the evolution of the concept.
Zhou T; Wang HW; Pittaluga S; Jaffe ES
Pathologica; 2021 Oct; 113(5):339-353. PubMed ID: 34837092
[TBL] [Abstract][Full Text] [Related]
56. Is tocilizumab a potential therapeutic option for refractory unicentric Castleman disease?
Abid MB; Peck R; Abid MA; Al-Sakkaf W; Zhang Y; Dunnill GS; Staines K; Sequeiros IM; Lowry L
Hematol Oncol; 2018 Feb; 36(1):320-323. PubMed ID: 28401573
[TBL] [Abstract][Full Text] [Related]
57. Clinical, laboratory and imaging findings in Castleman's disease - The subtype decides.
Haap M; Wiefels J; Horger M; Hoyer A; Müssig K
Blood Rev; 2018 May; 32(3):225-234. PubMed ID: 29223447
[TBL] [Abstract][Full Text] [Related]
58. Peripheral helper-T-cell-derived CXCL13 is a crucial pathogenic factor in idiopathic multicentric Castleman disease.
Harada T; Kikushige Y; Miyamoto T; Uno K; Niiro H; Kawakami A; Koga T; Akashi K; Yoshizaki K
Nat Commun; 2023 Oct; 14(1):6959. PubMed ID: 37907518
[TBL] [Abstract][Full Text] [Related]
59. Human Herpesvirus Type 8-positive Multicentric Castleman Disease.
Melikyan AL; Egorova EK; Julhakyan HL; Kovrigina AL; Savchenko VG
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S159-65. PubMed ID: 27133959
[TBL] [Abstract][Full Text] [Related]
60. The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry.
Fajgenbaum DC; Pierson SK; Kanhai K; Bagg A; Alapat D; Lim MS; Lechowicz MJ; Srkalovic G; Uldrick TS; van Rhee F;
Br J Haematol; 2022 Jul; 198(2):307-316. PubMed ID: 35507638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
